Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Research Partnership’s MedTech Division appoints two Directors

    May 14, 2021 | Medtech, News, Staff announcement 

    Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.

    We are delighted to announce that Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.

    Chris has over 27 years’ experience in healthcare research and consulting and his peers acknowledge him to be a strategic thinker with a demonstrated ability to leverage primary and secondary market research, connecting disparate pieces of information to form a clear picture. He most recently served as Vice President, Strategic Research Services for the KJT Group and his other professional experiences include roles with a product design consultancy, independent moderating, Becton Dickinson and with J&J’s Ethicon Endo-Surgery.

    Andrew is a seasoned market research professional with over 13 years’ experience in healthcare research and consulting. He has experience of working across a broad range of therapy areas and devices and has previously focused on both quantitative and qualitative research. Andrew has previously worked at InStar Research and Medex Research.

    Head of MedTech Division, Sabera Hyderally said of the appointment, “I am delighted to welcome both Chris and Andrew to the MedTech division. They bring a wealth of experience, deep knowledge and fresh ideas and I’m excited to partner with researchers of their calibre as we continue our tremendous growth globally.”

    Founding Director Mary Assimakopoulos added, “We are very pleased that both Chris and Andrew have chosen to join Research Partnership. They have both previously worked with a range of MedTech clients and bring a great depth of experience to the team, which aims to stay at the forefront of best practice and innovation.”

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

    Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

    Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

    As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

    How DataGateway unified oncology data for real-world insights & market intelligence

    Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.

    Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

    Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

    ESMO 2025 highlights: How storytelling, design & emotion are transforming scientific engagement

    Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.

    Preparing for ASH 2025: Pharma’s role in hematology innovation

    As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

    AI without limits: A smarter, integrated approach to Medical Affairs

    At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...

    What to expect from Obesity Week 2025: Key trends shaping the future of obesity care

    Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.

    AI with intent: How Inizio is redefining pharma through precision and partnership

    At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...

    Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight

    Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.